Clinical Trial Update: Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating interferon-α for TP53-mutant myeloid malignancies after allogeneic stem cell transplantation is currently recruiting in China.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes
• Myeloid Leukemia

Drugs mentioned

• Interferon (interferon)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Myeloid Leukemia, Myelodysplastic Syndromes | Phase 2 | Status: RECRUITING